{"id":7749,"date":"2026-04-28T16:47:46","date_gmt":"2026-04-28T13:47:46","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=7749"},"modified":"2026-04-28T16:47:47","modified_gmt":"2026-04-28T13:47:47","slug":"sgt-003-eu-orphan-drug-duchenne","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/fr\/sgt-003-eu-orphan-drug-duchenne\/","title":{"rendered":"La Commission europ\u00e9enne accorde la d\u00e9signation de m\u00e9dicament orphelin au SGT-003 pour le traitement de la dystrophie musculaire de Duchenne."},"content":{"rendered":"<p class=\"wp-block-paragraph\"><strong>La Commission europ\u00e9enne a accord\u00e9 la d\u00e9signation de m\u00e9dicament orphelin au SGT-003, une th\u00e9rapie g\u00e9nique prometteuse d\u00e9velopp\u00e9e par Solid Biosciences, pour le traitement de la dystrophie musculaire de Duchenne (DMD).<\/strong>. Cette \u00e9tape importante souligne le soutien r\u00e9glementaire croissant aux th\u00e9rapies innovantes ciblant les maladies rares pr\u00e9sentant d&#039;importants besoins m\u00e9dicaux non satisfaits.<\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>Table des mati\u00e8res<\/h2><nav><ul><li><a href=\"#what-is-sgt-003\">Qu&#039;est-ce que SGT-003 ?<\/a><\/li><li><a href=\"#regulatory-milestone-orphan-drug-designation\">\u00c9tape r\u00e9glementaire importante\u00a0: D\u00e9signation de m\u00e9dicament orphelin<\/a><\/li><li><a href=\"#global-regulatory-momentum\">Dynamique r\u00e9glementaire mondiale<\/a><\/li><li><a href=\"#ongoing-clinical-trials\">Essais cliniques en cours<\/a><\/li><li><a href=\"#why-this-matters-for-duchenne-patients\">Pourquoi c&#039;est important pour les patients atteints de dystrophie musculaire de Duchenne<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"what-is-sgt-003\"><strong>Qu&#039;est-ce que SGT-003 ?<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">SGT-003 est une th\u00e9rapie g\u00e9nique exp\u00e9rimentale con\u00e7ue pour traiter la cause g\u00e9n\u00e9tique sous-jacente de la dystrophie musculaire de Duchenne (DMD). Cette th\u00e9rapie vise \u00e0 fournir une version fonctionnelle du g\u00e8ne de la dystrophine, ce qui pourrait am\u00e9liorer la fonction musculaire et ralentir la progression de la maladie. En savoir plus\u00a0: <a href=\"https:\/\/dmdwarrior.com\/fr\/faq-solid-biosciences-sgt-003-gene-therapy\/\" target=\"_blank\" rel=\"noreferrer noopener\">Questions fr\u00e9quentes sur la th\u00e9rapie g\u00e9nique SGT-003<\/a><\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"regulatory-milestone-orphan-drug-designation\"><strong>\u00c9tape r\u00e9glementaire importante\u00a0: D\u00e9signation de m\u00e9dicament orphelin<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">La d\u00e9signation de m\u00e9dicament orphelin accord\u00e9e par la Commission europ\u00e9enne fait suite \u00e0 un avis favorable du Comit\u00e9 des m\u00e9dicaments orphelins de l&#039;Agence europ\u00e9enne des m\u00e9dicaments.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Cette d\u00e9signation offre plusieurs avantages cl\u00e9s\u00a0:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Exclusivit\u00e9 de march\u00e9 dans l&#039;UE<\/li>\n\n\n\n<li>Frais r\u00e9glementaires r\u00e9duits<\/li>\n\n\n\n<li>Acc\u00e8s \u00e0 l&#039;assistance protocolaire<\/li>\n\n\n\n<li>Soutien au d\u00e9veloppement am\u00e9lior\u00e9<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Selon Jessie Hanrahan, cette reconnaissance renforce le potentiel du SGT-003 pour r\u00e9pondre aux besoins critiques non satisfaits des patients atteints de dystrophie musculaire de Duchenne dans le monde entier.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"global-regulatory-momentum\"><strong>Dynamique r\u00e9glementaire mondiale<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Le SGT-003 a re\u00e7u de multiples d\u00e9signations r\u00e9glementaires sur les principaux march\u00e9s, t\u00e9moignant d&#039;une forte harmonisation internationale\u00a0:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>De la part de l&#039;Agence am\u00e9ricaine des produits alimentaires et m\u00e9dicamenteux (FDA)\u00a0:\n<ul class=\"wp-block-list\">\n<li>D\u00e9signation \u00ab\u00a0voie rapide\u00a0\u00bb<\/li>\n\n\n\n<li>d\u00e9signation de m\u00e9dicament orphelin<\/li>\n\n\n\n<li>d\u00e9signation de maladie p\u00e9diatrique rare<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li>D&#039;apr\u00e8s le cadre r\u00e9glementaire britannique\u00a0:\n<ul class=\"wp-block-list\">\n<li>Passeport d\u2019innovation dans le cadre du programme de licence d\u2019innovation et de voie d\u2019acc\u00e8s<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Ces d\u00e9signations acc\u00e9l\u00e8rent les d\u00e9lais de d\u00e9veloppement et facilitent une collaboration plus \u00e9troite avec les organismes de r\u00e9glementation.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"ongoing-clinical-trials\"><strong>Essais cliniques en cours<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Le SGT-003 est actuellement \u00e9valu\u00e9 dans le cadre de deux \u00e9tudes cliniques majeures\u00a0:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong><a href=\"https:\/\/dmdwarrior.com\/fr\/solid-biosciences-provides-update-on-inspire-duchenne-clinical-trial-progress-and-planned-regulatory-discussions\/\">INSPIRE DUCHENNE<\/a><\/strong><br>Essai de phase 1\/2 \u00e9valuant la s\u00e9curit\u00e9 et l&#039;efficacit\u00e9 pr\u00e9coce<\/li>\n\n\n\n<li><strong><a href=\"https:\/\/dmdwarrior.com\/fr\/solid-biosciences-sgt-003-gene-therapy-phase-3-clinical-trial-nct07160634\/\">IMPACT DUCHENNE<\/a><\/strong><br>Essai randomis\u00e9 de phase 3, en double aveugle, contr\u00f4l\u00e9 par placebo<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Ces essais sont con\u00e7us pour appuyer les approbations r\u00e9glementaires dans plusieurs r\u00e9gions.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"why-this-matters-for-duchenne-patients\"><strong>Pourquoi c&#039;est important pour les patients atteints de dystrophie musculaire de Duchenne<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">La dystrophie musculaire de Duchenne est une maladie g\u00e9n\u00e9tique grave et \u00e9volutive pour laquelle les options th\u00e9rapeutiques sont limit\u00e9es. Le d\u00e9veloppement de th\u00e9rapies g\u00e9niques comme le SGT-003 repr\u00e9sente un changement de paradigme potentiel, passant de la gestion des sympt\u00f4mes \u00e0 des interventions modifiant l&#039;\u00e9volution de la maladie.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Suivre cette page<\/strong>&nbsp;&gt;&gt;&gt;&nbsp;<a href=\"https:\/\/dmdwarrior.com\/fr\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Tous les essais cliniques pour la dystrophie musculaire de Duchenne<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>The European Commission has granted Orphan Drug Designation to SGT-003, a promising gene therapy developed by Solid Biosciences, for the treatment of Duchenne muscular dystrophy (DMD). This milestone highlights growing regulatory support for innovative therapies targeting rare diseases with high unmet medical needs. What Is SGT-003? SGT-003 is an investigational gene therapy designed to address [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":7750,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[680,61,195,681,110,170,109],"class_list":["post-7749","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-dmd-orphan-drugs","tag-gene-therapy","tag-orphan-drug","tag-orphan-drug-designation","tag-sgt-003","tag-sgt-003-gene-therapy","tag-solid-biosciences"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/7749","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/comments?post=7749"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/7749\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media\/7750"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media?parent=7749"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/categories?post=7749"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/tags?post=7749"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}